These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23157634)

  • 1. Proton magnetic resonance spectroscopy changes after antipsychotic treatment.
    Szulc A; Galinska-Skok B; Waszkiewicz N; Bibulowicz D; Konarzewska B; Tarasow E
    Curr Med Chem; 2013; 20(3):414-27. PubMed ID: 23157634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton magnetic resonance spectroscopy measures related to short-term symptomatic outcome in chronic schizophrenia.
    Szulc A; Konarzewska B; Galinska-Skok B; Lazarczyk J; Waszkiewicz N; Tarasow E; Milewski R; Walecki J
    Neurosci Lett; 2013 Jun; 547():37-41. PubMed ID: 23665527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment.
    Szulc A; Galinska B; Tarasow E; Waszkiewicz N; Konarzewska B; Poplawska R; Bibulowicz D; Simonienko K; Walecki J
    Pharmacopsychiatry; 2011 Jun; 44(4):148-57. PubMed ID: 21710405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS).
    Szulc A; Galinska B; Tarasow E; Dzienis W; Kubas B; Konarzewska B; Walecki J; Alathiaki AS; Czernikiewicz A
    Pharmacopsychiatry; 2005 Sep; 38(5):214-9. PubMed ID: 16189748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia.
    Strzelecki D; Podgórski M; Kałużyńska O; Gawlik-Kotelnicka O; Stefańczyk L; Kotlicka-Antczak M; Gmitrowicz A; Grzelak P
    Nutrients; 2015 Oct; 7(10):8767-82. PubMed ID: 26506383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-acetylaspartate (NAA) levels in selected areas of the brain in patients with chronic schizophrenia treated with typical and atypical neuroleptics: a proton magnetic resonance spectroscopy (1H MRS) study.
    Szulc A; Galińska B; Tarasów E; Kubas B; Dzienis W; Konarzewska B; Poplawska R; Tomczak AA; Czernikiewicz A; Walecki J
    Med Sci Monit; 2007 May; 13 Suppl 1():17-22. PubMed ID: 17507880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex.
    Strzelecki D; Podgórski M; Kałużyńska O; Stefańczyk L; Kotlicka-Antczak M; Gmitrowicz A; Grzelak P
    Int J Mol Sci; 2015 Oct; 16(10):24475-89. PubMed ID: 26501260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction.
    Plitman E; de la Fuente-Sandoval C; Reyes-Madrigal F; Chavez S; Gómez-Cruz G; León-Ortiz P; Graff-Guerrero A
    Schizophr Bull; 2016 Mar; 42(2):415-24. PubMed ID: 26320195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1H-MRS at 4 tesla in minimally treated early schizophrenia.
    Bustillo JR; Rowland LM; Mullins P; Jung R; Chen H; Qualls C; Hammond R; Brooks WM; Lauriello J
    Mol Psychiatry; 2010 Jun; 15(6):629-36. PubMed ID: 19918243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy.
    Tandon N; Bolo NR; Sanghavi K; Mathew IT; Francis AN; Stanley JA; Keshavan MS
    Schizophr Res; 2013 Aug; 148(1-3):59-66. PubMed ID: 23791389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton magnetic resonance spectroscopy changes after lithium treatment. Systematic review.
    Szulc A; Wiedlocha M; Waszkiewicz N; Galińska-Skok B; Marcinowicz P; Gierus J; Mosiolek A
    Psychiatry Res Neuroimaging; 2018 Mar; 273():1-8. PubMed ID: 29414126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia.
    Bustillo JR; Rowland LM; Jung R; Brooks WM; Qualls C; Hammond R; Hart B; Lauriello J
    Neuropsychopharmacology; 2008 Sep; 33(10):2456-66. PubMed ID: 18094668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The influence of atypical antipsychotics on brain functioning in schizophrenia. A proton magnetic resonance study].
    Szulc A; Galińiska B; Tarasów E; Dzienis W; Kubas B; Konarzewska B; Waszkiewicz N; Popławska R
    Psychiatr Pol; 2010; 44(3):415-26. PubMed ID: 20672520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supplementation of antipsychotic treatment with sarcosine – GlyT1 inhibitor – causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia.
    Strzelecki D; Podgórski M; Kałużyńska O; Gawlik-Kotelnicka O; Stefańczyk L; Kotlicka-Antczak M; Gmitrowicz A; Grzelak P
    Neurosci Lett; 2015 Oct; 606():7-12. PubMed ID: 26306650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.
    Plitman E; Chavez S; Nakajima S; Iwata Y; Chung JK; Caravaggio F; Kim J; Alshehri Y; Chakravarty MM; De Luca V; Remington G; Gerretsen P; Graff-Guerrero A
    Psychiatry Res Neuroimaging; 2018 Mar; 273():16-24. PubMed ID: 29414127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS).
    Tayoshi S; Sumitani S; Taniguchi K; Shibuya-Tayoshi S; Numata S; Iga J; Nakataki M; Ueno S; Harada M; Ohmori T
    Schizophr Res; 2009 Mar; 108(1-3):69-77. PubMed ID: 19097753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Metabolite Concentrations in the Left Dorsolateral Prefrontal Cortex, the Left Frontal White Matter, and the Left Hippocampus in Patients in Stable Schizophrenia Treated with Antipsychotics with or without Antidepressants. ¹H-NMR Spectroscopy Study.
    Strzelecki D; Grzelak P; Podgórski M; Kałużyńska O; Stefańczyk L; Kotlicka-Antczak M; Gmitrowicz A
    Int J Mol Sci; 2015 Oct; 16(10):24387-402. PubMed ID: 26501256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
    Ohrmann P; Siegmund A; Suslow T; Pedersen A; Spitzberg K; Kersting A; Rothermundt M; Arolt V; Heindel W; Pfleiderer B
    J Psychiatr Res; 2007 Oct; 41(8):625-34. PubMed ID: 16949099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of repeated dizocilpine treatment on glutamatergic activity in the prefrontal cortex in an animal model of schizophrenia: An in vivo proton magnetic resonance spectroscopy study at 9.4T.
    Yoo CH; Song KH; Lim SI; Lee DW; Woo DC; Choe BY
    Neurosci Lett; 2017 Jan; 637():57-63. PubMed ID: 27894920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton magnetic resonance spectroscopy as a probe into the pathophysiology of autism spectrum disorders (ASD): a review.
    Baruth JM; Wall CA; Patterson MC; Port JD
    Autism Res; 2013 Apr; 6(2):119-33. PubMed ID: 23436782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.